Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh
- “I think that we just got lucky there, I suppose!”—Choosing Esketamine as a Candidate; From Academia to Industry
- Public Interest in Ketamine; Off-Label Use
- Effect Sizes; “Jaz’s law”
- Spravato with Psychological Support?
- Advice for Psychedelic Drug Developers
- Maintenance of Effect
- Predicting Patient Response
- NICE’s Repeated Rejection of Spravato Coverage in the UK
- Closing Thoughts
Psychedelic Alpha’s Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, Vice President Psychiatry Development at Neurocrine Biosciences.
For the purposes of this conversation, however, we focus on Singh’s role in spearheading the development of esketamine for treatment-resistant depression, now marketed as Spravato.
Here, we discuss how Singh’s early work assessing ketamine’s antidepressant effects at the National Institute of Mental Health (NIMH) encouraged him to move into industry; how his team decided to pursue esketamine; lessons learned that might be relevant for psychedelic drug developers; and his broader outlook on the field.
(Editor’s note: Given the length of this interview, we decided that—rather than paring it down—we would include sub-headings that hint at the broad theme of each question...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks